-
Recent Posts
- A Renaissance in Chronic Kidney Disease Treatment Is Underway
- Akebia Therapeutics Announces Approval of Vadadustat in Japan for the Treatment of Anemia Due to Chronic Kidney Disease in Dialysis-Dependent and Non-Dialysis Dependent Adult Patients
- Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis
- A proposed clinical trial for COVID-19 pneumonia
- Dapagliflozin–saxagliptin ‘attractive’ options for patients with type 2 diabetes with chronic kidney disease
Recent Comments
Archives
- January 2021
- July 2020
- May 2020
- April 2020
- May 2019
- February 2019
- January 2019
- November 2018
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- December 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- November 2012
- October 2012
- May 2012
- December 2011
- May 2011
Categories
Meta
Monthly Archives: November 2018
AstraZeneca Reports Full Results from DECLARE-TIMI 58 Cardiovascular Outcomes Trial for FARXIGA (dapagliflozin)
November 12, 2018; Reproduced from StreetInsider AstraZeneca today announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for FARXIGA (dapagliflozin). The data were presented as a late-breaking abstract (#19485) at the American Heart Association (AHA) Scientific Sessions … Continue reading
Posted in M Loghman-Adham, MD
Leave a comment
Lokelma approved in the US for the treatment of adults with hyperkalemia
On May 18, 2018 AstraZeneca announced the FDA approval of their new drug Lokelma, for the treatment of hyperkalemia. The full new release is reproduced below: The US Food and Drug Administration (FDA) has approved Lokelma (sodium zirconium cyclosilicate), formerly ZS-9, for … Continue reading
Posted in M Loghman-Adham, MD
Leave a comment